116,276 Shares in Eikon Therapeutics, Inc. $EIKN Acquired by Comprehensive Financial Management LLC

Comprehensive Financial Management LLC acquired a new stake in Eikon Therapeutics, Inc. (NASDAQ:EIKN) during the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor acquired 116,276 shares of the company’s stock, valued at approximately $1,517,000. Eikon Therapeutics comprises 0.0% of Comprehensive Financial Management LLC’s investment portfolio, making the stock its 26th largest position.

Several other institutional investors and hedge funds have also bought and sold shares of the company. Parkman Healthcare Partners LLC bought a new position in Eikon Therapeutics during the second quarter valued at $3,341,000. Legal & General Group Plc bought a new stake in shares of Eikon Therapeutics in the second quarter valued at $28,000. The Manufacturers Life Insurance Company raised its stake in shares of Eikon Therapeutics by 23.5% in the second quarter. The Manufacturers Life Insurance Company now owns 35,357 shares of the company’s stock valued at $461,000 after buying an additional 6,734 shares during the period. BlackRock Inc. lifted its position in shares of Eikon Therapeutics by 29.0% during the 2nd quarter. BlackRock Inc. now owns 4,281,425 shares of the company’s stock valued at $55,873,000 after buying an additional 962,046 shares during the last quarter. Finally, Deutsche Bank AG purchased a new position in shares of Eikon Therapeutics during the 2nd quarter valued at $281,000.

Analyst Upgrades and Downgrades

Several brokerages recently weighed in on EIKN. Wedbush decreased their price objective on Eikon Therapeutics from $5.00 to $4.00 and set an “underperform” rating for the company in a report on Friday, August 14th. Weiss Ratings raised shares of Eikon Therapeutics from a “sell (e-)” rating to a “sell (e)” rating in a report on Monday, August 3rd. Finally, Cantor Fitzgerald reiterated an “overweight” rating on shares of Eikon Therapeutics in a research report on Friday, August 21st. Five equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and two have assigned a Sell rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and an average target price of $25.00.

Eikon Therapeutics Price Performance

Eikon Therapeutics stock opened at $10.88 on Wednesday. The firm has a 50 day simple moving average of $10.59. Eikon Therapeutics, Inc. has a 1-year low of $7.90 and a 1-year high of $17.40. The stock has a market cap of $589.37 million and a price-to-earnings ratio of -2.66.

Eikon Therapeutics (NASDAQ:EIKN) last posted its earnings results on Thursday, August 13th. The company reported ($1.63) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.61) by ($0.02). Equities research analysts anticipate that Eikon Therapeutics, Inc. will post -7.24 earnings per share for the current fiscal year.

About Eikon Therapeutics

We are a late-stage clinical biopharmaceutical company dedicated to building a global, fully-integrated organization developing important, innovative medicines to address serious unmet medical needs. We are led by world-renowned drug developers Dr. Roger M. Perlmutter, M.D., Ph.D., and Dr. Roy Baynes, M.D., Ph.D. Our vision is to become a generational leader, by purposefully integrating traditional biology research with advanced engineering to develop better medicines faster. Our initial focus is oncology, where we are advancing a pipeline of drug candidates targeting areas of high unmet need in large indications.